Evan Seigerman
Stock Analyst at BMO Capital
Total Price Targets
30
Stocks Covered
14
Sectors
Healthcare
Most Recent
Feb 17, 2026
Notable Calls (Last 12 Months)
Most Bullish
Stocks Covered by Evan Seigerman
| Symbol | Company | Latest Target | Current Price | Upside | # Targets | Last Updated |
|---|---|---|---|---|---|---|
| IRON | Disc Medicine, Inc. | $100.00 | $67.31 | +48.6% | 1 | Feb 17, 2026 |
| GILD | Gilead Sciences, Inc. | $160.00 | $132.04 | +21.2% | 1 | Feb 11, 2026 |
| BIIB | Biogen Inc. | $196.00 | $186.69 | +5.0% | 3 | Feb 6, 2026 |
| LLY | Eli Lilly and Company | $1300.00 | $961.67 | +35.2% | 3 | Feb 5, 2026 |
| REGN | Regeneron Pharmaceuticals, Inc. | $850.00 | $703.72 | +20.8% | 2 | Dec 4, 2025 |
| AMGN | Amgen Inc. | $372.00 | $328.69 | +13.2% | 2 | Dec 3, 2025 |
| REPL | Replimune Group, Inc. | $11.00 | $2.46 | +348.1% | 3 | Nov 3, 2025 |
| TERN | Terns Pharmaceuticals, Inc. | $22.00 | $52.94 | -58.4% | 1 | Nov 3, 2025 |
| MRK | Merck & Co., Inc. | $82.00 | $111.89 | -26.7% | 1 | Apr 25, 2025 |
| ABBV | AbbVie Inc. | $215.00 | $206.29 | +4.2% | 3 | Feb 3, 2025 |
| VRTX | Vertex Pharmaceuticals Incorporated | $545.00 | $425.06 | +28.2% | 2 | Jan 31, 2025 |
| BMY | Bristol-Myers Squibb Company | $61.00 | $58.22 | +4.8% | 4 | Nov 12, 2024 |
| INCY | Incyte Corporation | $48.00 | $96.41 | -50.2% | 2 | Jul 2, 2024 |
| PFE | Pfizer Inc. | $36.00 | $26.38 | +36.5% | 2 | May 22, 2024 |
Recent Activity
- Feb 17, 2026— Set$100.00price target onIRON(Disc Medicine, Inc.)
- Feb 11, 2026— Set$160.00price target onGILD(Gilead Sciences, Inc.)
- Feb 6, 2026— Set$196.00price target onBIIB(Biogen Inc.)
- Feb 5, 2026— Set$1300.00price target onLLY(Eli Lilly and Company)
- Dec 4, 2025— Set$850.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Dec 3, 2025— Set$372.00price target onAMGN(Amgen Inc.)
- Dec 2, 2025— Set$1100.00price target onLLY(Eli Lilly and Company)
- Nov 3, 2025— Set$22.00price target onTERN(Terns Pharmaceuticals, Inc.)
- Nov 3, 2025— Set$11.00price target onREPL(Replimune Group, Inc.)
- Oct 29, 2025— Set$725.00price target onREGN(Regeneron Pharmaceuticals, Inc.)
- Apr 25, 2025— Set$82.00price target onMRK(Merck & Co., Inc.)
- Feb 3, 2025— Set$215.00price target onABBV(AbbVie Inc.)
- Jan 31, 2025— Set$545.00price target onVRTX(Vertex Pharmaceuticals Incorporated)
- Jan 22, 2025— Set$27.00price target onREPL(Replimune Group, Inc.)
- Nov 12, 2024— Set$61.00price target onBMY(Bristol-Myers Squibb Company)
- Oct 17, 2024— Set$230.00price target onBIIB(Biogen Inc.)
- Jul 19, 2024— Set$214.00price target onABBV(AbbVie Inc.)
- Jul 2, 2024— Set$48.00price target onINCY(Incyte Corporation)
- May 22, 2024— Set$36.00price target onPFE(Pfizer Inc.)
- May 17, 2024— Set$14.00price target onREPL(Replimune Group, Inc.)
Frequently Asked Questions
Who is Evan Seigerman?
Evan Seigerman is a stock analyst at BMO Capital covering 14 stocks primarily in Healthcare. They have issued 30 price targets since Jan 15, 2022.
What stocks does Evan Seigerman cover?
Evan Seigerman currently covers 14 stocks, including BMY, BIIB, LLY, REPL, ABBV.
What is Evan Seigerman's latest price target?
Evan Seigerman's most recent price target was $100.00 on IRON (Disc Medicine, Inc.), set on Feb 17, 2026.
What is Evan Seigerman's highest price target?
Evan Seigerman's highest issued price target is $1300.00 on LLY, set on Feb 5, 2026.
More Analysts at BMO Capital
Coverage based on publicly published price targets. Not investment advice.